



Alcidion Group Limited

Wholesale Investor Presentation

May 2016



Disclaimer

This presentation has been prepared by Alcidion Group Limited (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other Jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.



Nathan Buzza
Executive Director
Alcidion Corporation

nathan.buzza@alcidion.com


Mobile +61 4 8886 2222

www.alcidion.com



Executive Summary





ASX Ticker

ALC

Market Capitalisation

\$30m

Ownership

40% Founders

15% BlueSky Private Equity

9% Owned by Employees

6% Allure Capital

Share Price

5.00c

Cash on hand

\$6.00m

Enterprise Value

\$24m

Shares on Issue

603m

FY15 Revenues

\$5.05m, Audited

FY15 EBITDA

\$183k Loss, Audited

Employees

32 x FTE, 2 x Contractors

R&D Investment

~\$15m, Unaudited

Prior Funding

\$15.48m

Performance Shares

\$4m in script on achieving \$10m in revenue within 2 years and;

\$4m in script on achieving \$15m in revenue within 3 years.

All financial data has been rounded as of 27th April 2016



**Chief Medical Officer
Prof. Malcolm Pradhan**

- Formal qualifications in medicine complimented by a PhD in Medical Informatics from Stanford University.
- Founding fellow of the Australasian College of Health Informatics.
- Associate Dean of IT & Director of Medical Informatics at the University of Adelaide.
- Clinical Lead within the Australian Government's National e-Health Transition Authority.



**Chief Executive Officer
Mr. Ray Blight**

- Formal qualifications include a Bachelor of Technology, Bachelor of Economics and a MBA.
- Former CEO of the South Australian Health Commission and Chair of the Health Ministers' Advisory Council
- Consultant to the World Bank.
- Chairs the University of SA IT & Mathematical Sciences Advisory Board.



**Executive Director
Mr. Nathan Buzza**

- Former CEO of Clinical Middleware provider, Commtech Wireless.
- EY "Entrepreneur of the Year" in both 2002 & 2005.
- BRW in the "Fast100", for three consecutive years.
- WA IT & telecommunications Life Time achievement Award for contribution to the IT community.
- Previously the second largest shareholder of Azure Healthcare ([ASX:AZV](https://www.asx.com.au/asx/azv)).



**Non-Executive Director
Mr. Nick Dignam**

- Formal qualifications include a Bachelor of Commerce, Bachelor of Law and a Masters of Applied Finance.
- Investment Director of BlueSky, a listed alternative asset manager with \$1b of assets under management.
- Responsible for originating new investment opportunities, working with portfolio companies to deliver growth and managing exit processes.
- Nick joined Blue Sky from Catalyst Investment Managers.

- Hospitals are built upon a complex eco-system of disparate Clinical Information Systems (CIS).
- Alcidion's Miya platform integrates disparate Clinical Information Systems to identify emerging clinical risk and push this clinical intelligence to the care team via a continuum of devices.
- Under the stewardship of our CMO, Professor Malcolm Pradhan and CEO Ray Blight, the former Chief Executive of the SA Health Commission, Alcidion has invested over \$15m in the development of the Miya Platform.
- The technology is already deployed and operational at Western Health, Northern Territory Health Department, Tasmania Health and the Royal Melbourne.
- The company enjoyed \$5m in revenues in FY15 from the deployment of the platform into beta sites.



- Global expenditure on Healthcare IT is \$USD40.4b, growing to \$USD56.7b by 2017.
- Mobile Health technology is growing from \$USD6.9b market in 2014 to \$USD23b market by 2017.
- The Clinical Decision Support Systems Market is set to grow 21.5% CAGR from \$USD1.18b in 2013 to \$USD4.65b by 2018 (IndustryARC)
- One third of all hospitals in the USA are planning to invest in Patient Flow Solutions (Capsite, division of HIMSS).
- These trends are likely to repeat in other major western style health systems



A man with short brown hair, wearing a white button-down shirt and blue jeans, is sitting in a brown leather armchair. He is smiling and has his hands clasped in his lap. He is wearing a watch on his left wrist and brown suede shoes. The chair is positioned in front of a large window that looks out onto a city skyline. The floor is covered with a blue and white patterned rug.

“At BlueSky we meticulously evaluate every opportunity. Alcidion ticked all the boxes: Mobile, Healthcare, Information Technology, coupled with an internationally recognized Management Team.”

Nick Dignam
Investment Director
Blue Sky Private Equity

BlueSky
Alternative Thinking

“What really struck me about Alcidion was the deep seated passion of the founders to fix healthcare – coupled with their impeccable qualifications”

Nathan Buzza
Allure Capital



“...the Miya platform is creating a great deal of interest. It’s being used in hospitals across Australia and New Zealand, and there’s a possibility it will be trialed here in South Australia soon.”

Jay Weatherill MP
Premier of South Australia



The background of the slide features a doctor in a white lab coat and a striped tie, with a stethoscope around their neck. Overlaid on this is a network diagram with a central blue circle containing the text 'AFFORDABLE CARE ACT'. This central circle is connected by lines to several other circular icons: a blue Star of Life (EMS symbol), a pill bottle, a blue drop with a plus sign, two crossed pills, a heart rate line, and a simple blue plus sign. In the top left corner, there is a small orange speech bubble icon.

Unique Opportunity To Be Part of the New Digital Health Economy

The introduction of the Patient Protection & Affordable Care Act 2010 (“Obamacare”) requires US hospitals to adopt Electronic Medical Records or face a reduction in Medicare reimbursements.

Experienced Management Team



“Capable and Experienced Management Team with a strong track record of commercializing healthcare software, including the former CEO & Chairman of the South Australian Health Commission, a Stanford qualified Medical Doctor and a former Ernst & Young Entrepreneur of the Year.”

Proven Technology

Alcidion's platform is installed into 11 large tertiary hospitals including Footscray, Sunshine, Williamstown, Royal Darwin & Alice Springs Hospitals and throughout Tasmania.

Disruptive Technology Platform

A person wearing a white hospital gown and a wristband is lying in a hospital bed. They are holding a tablet computer with both hands. The tablet screen displays a medical dashboard with various charts, graphs, and data points. The background is slightly blurred, showing the hospital bed and some papers.

The platform is at the forefront of medical technology, on the crest of the next generation of healthcare technologies.

Strong Growth Platform

The business recently secured a \$1.75m contract with the Northern Territory Health Department to roll out a pilot of the Computerised Physician Order Entry technology (CPOE).

Several new contracts are presently being negotiated with leading public and private hospitals throughout Australia and New Zealand.

Fully Funded

The recent listing of Alcidion on the ASX will see the company fully funded, with \$6.00m in cash and debt free.

